mRNA-Lipid Nanoparticle Cancer Vaccines: Mechanistic Principles, Clinical Translation and Emerging Design Rules

Therapeutic cancer vaccines have long promised durable, tumour-specific immunity but have repeatedly failed to deliver it in the clinic. The combination of synthetic messenger RNA (mRNA) with ionizable lipid nanoparticles (LNPs) has changed that trajectory. What began as a delivery solution for a fragile nucleic acid has become a programmable immunotherapy platform: an mRNA molecule encodes any antigen within days of sequence identification, and the LNP that carries it simultaneously serves as a potent, self-adjuvanting immunostimulant. This review integrates the mechanistic literature of the past five years with the maturing clinical dataset. We first dissect how LNP composition, intracellular trafficking and mRNA chemistry determine the amount, duration and anatomical location of antigen expression. We then examine the innate immune circuit that converts encapsulated RNA into a TH1-biased adjuvant signal, and explain why the same type I interferon (IFN-I)-PKR axis that licenses dendritic cell maturation also imposes a ceiling on antigen output. Building on this, we trace the path from cross-presentation by cDC1 to effector CD8+ T cell function inside the tumour, and we map the tumour-intrinsic and microenvironmental lesions that constrain efficacy. Clinically, individualised neoantigen therapy has produced the first randomised evidence of benefit in resected melanoma (KEYNOTE-942), while autogene cevumeran has shown that vaccine-expanded, long-lived neoantigen-specific CD8+ T cells can be generated in pancreatic cancer-a tumour previously regarded as vaccine-refractory. We synthesise these data into design rules that link antigen selection, LNP chemistry, dosing schedule and combination partner to the immunological objective, and we identify the mechanistic questions-extrahepatic targeting, repeat dosing, immunity to the carrier, and the definition of surrogate endpoints-that will determine whether mRNA-LNP vaccines become part of standard oncological care.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-18
DOI
https://doi.org/10.20944/preprints202611.1793.v1
Primary Topic
Immunotherapy and Immune Responses
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

mRNA-Lipid Nanoparticle Cancer Vaccines: Mechanistic Principles, Clinical Translation and Emerging Design Rules

Chenlin Xiu, 程宏献, Yunwang Zhao, Baihai Huang et al.
Preprints.org
Immunotherapy and Immune Responses
preprint

mRNA-Lipid Nanoparticle Cancer Vaccines: Mechanistic Principles, Clinical Translation and Emerging Design Rules

Chenlin Xiu, 程宏献, Yunwang Zhao, Baihai Huang, Xiongxiong Lu, Lei He, Shiyi Zhou
preprint en

Abstract

Therapeutic cancer vaccines have long promised durable, tumour-specific immunity but have repeatedly failed to deliver it in the clinic. The combination of synthetic messenger RNA (mRNA) with ionizable lipid nanoparticles (LNPs) has changed that trajectory. What began as a delivery solution for a fragile nucleic acid has become a programmable immunotherapy platform: an mRNA molecule encodes any antigen within days of sequence identification, and the LNP that carries it simultaneously serves as a potent, self-adjuvanting immunostimulant. This review integrates the mechanistic literature of the past five years with the maturing clinical dataset. We first dissect how LNP composition, intracellular trafficking and mRNA chemistry determine the amount, duration and anatomical location of antigen expression. We then examine the innate immune circuit that converts encapsulated RNA into a TH1-biased adjuvant signal, and explain why the same type I interferon (IFN-I)-PKR axis that licenses dendritic cell maturation also imposes a ceiling on antigen output. Building on this, we trace the path from cross-presentation by cDC1 to effector CD8+ T cell function inside the tumour, and we map the tumour-intrinsic and microenvironmental lesions that constrain efficacy. Clinically, individualised neoantigen therapy has produced the first randomised evidence of benefit in resected melanoma (KEYNOTE-942), while autogene cevumeran has shown that vaccine-expanded, long-lived neoantigen-specific CD8+ T cells can be generated in pancreatic cancer-a tumour previously regarded as vaccine-refractory. We synthesise these data into design rules that link antigen selection, LNP chemistry, dosing schedule and combination partner to the immunological objective, and we identify the mechanistic questions-extrahepatic targeting, repeat dosing, immunity to the carrier, and the definition of surrogate endpoints-that will determine whether mRNA-LNP vaccines become part of standard oncological care.

Preprints.org
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon